Soliris (eculizumab) is an antibody pharmaceutical. Eculizumab was first approved as Soliris on 2007-03-16. It is used to treat atypical hemolytic uremic syndrome and paroxysmal hemoglobinuria in the USA. It has been approved in Europe to treat paroxysmal hemoglobinuria. The pharmaceutical is active against complement C5.
|Indication||atypical hemolytic uremic syndrome, paroxysmal hemoglobinuria|
|Drug Class||Monoclonal antibodies: humanized, immunomodulating|